Can Gilead get past its oncology woes with anito-cel readout?

The CAR-T therapy for multiple myeloma has multibillion-dollar sales potential

October 25, 2024 Check out STAT+

Sponsored By

Justin Sullivan/Getty Images STAT+ | Gilead needs a win with Arcellx CAR-T data. Here's how to know if it scores Anito-cel has multibillion-dollar sales potential, if it proves to be competitive on efficacy and safer from a neurotoxicity perspective than Carvykti. By Adam Feuerstein STAT+ | Q&A: Mark Cuban explains his beef with traditional PBMs — and why he thinks disruption is inevitable The billionaire best known for his past role on the TV show "Shark Tank" is seeking to disrupt the system around prescription drug sales in the U.S. By STAT Staff Drinking is cheaper than it's been in decades. Lobbyists are fighting to keep it that way State and local taxes on alcoholic drinks haven't kept up with inflation because of the alcohol lobby's influence in statehouses, campaign contributions. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser